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Background: The serine protease thrombin is central in the processes of 
hemostasis and thrombosis. To be useful, thrombin inhibitors should combine 
potency towards thrombin with selectivity towards other related enzymes such 
as trypsin. We previously reported the structure-based design of thrombin 
inhibitors with rigid, bicyclic core structures. These compounds were highly 
active towards thrombin, but showed only modest selectivity. 
Results: Here, we describe the rational design of selective thrombin inhibitors 
starting from the X-ray crystal structure of the complex between the previously 
generated lead molecule and thrombin. The lead molecule bound with a K, value 
of 90 nM and a selectivity of 7.8 for thrombin over trypsin. Our design led to 
inhibitors with improved activity and greatly enhanced selectivity. The binding 
mode for two of the new inhibitors was determined by X-ray crystallography of 
their complexes with thrombin. The results confirmed the structures predicted 
by molecular modeling and, together with the binding assays, provided profound 
insight into molecular recognition phenomena at the thrombin active site. 
Conclusions: A novel class of nonpeptidic, selective thrombin inhibitors has 
resulted from structure-based design and subsequent improvement of the initial 
lead molecule. These compounds, which are preorganized for binding to 
thrombin through a rigid, bicyclic or tricyclic central core, could aid in the devel- 
opment of new antithrombotic drugs. Correlative binding and X-ray structural 
studies within a series of related, highly preorganized inhibitors, which all prefer 
similar modes of association to thrombin, generate detailed information on the 
strength of individual intermolecular bonding interactions and their contribution 
to the overall free energy of complexation. 
Addresses: ‘Laboratorium fijr Organische Chemie, 
ETH-Zentrum, Universitatstrasse 16, 8092 Ziirich, 
Switzerland and *Pharma Division, Preclinical 
Research, F  Hoffmann-La Roche Ltd, 4002 Basel, 
Switzerland. 
Correspondence: Francois Diederich 
E-mail: diederich@org.chem.ethz.ch 
Key words: molecular recognition, protein X-ray 
crystallography, structure-based inhibitor design, 
thrombin inhibitors. 
Received: 21 February 1997 
Accepted: 24 March 1997 
Chemistry &  Biology April 1997, 4:287-295 
http://biomednet.com/elecref/1074552100400287 
0 Current Biology Ltd ISSN 1074-5521 
Introduction 
Thrombin is a trypsin-like serine protease that is central in 
the processes of hemostasis and thrombosis. In the blood 
coagulation cascade, it cleaves the protein fibrinogen at spe- 
cific arginine residues to give polymerizable fibrin, which is 
a major constituent of blood clots. Moreover, thrombin is 
the main activator of platelet aggregation and other coagula- 
tion factors [l]. Defects in the delicate balance between 
coagulation factors and their endogenous inhibitors can lead 
to serious complications such as the formation of thrombi in 
blood vessels. Thrombin is therefore an important pharma- 
ceutical target for the treatment and prevention of throm- 
botic diseases. The search for small, potentially orally 
bioavailable synthetic inhibitors of thrombin is especially 
intense [2,3]. X-ray crystal structures of thrombin-inhibitor 
complexes [4,5] show that the enzyme is a rather rigid 
protein with well-defined binding pockets in the active 
site. These properties make thrombin a particularly well- 
suited target for structure-based inhibitor design [6-81. 
We previously described [9] the rational design of novel, 
nonpeptidic thrombin inhibitors with rigid, bicyclic core 
structures. Although these compounds were highly active 
for thrombin, their selectivity for thrombin compared with 
the structurally related digestive enzyme trypsin was not 
satisfactory. The most active compound in this series, 
rat-1 (rat = racemic; Fig. l), bound to thrombin with 
Ki = 90nM and displayed a selectivity [KJtrypsin)/ 
K;(thrombin)] of 7.8. Other serine proteases in the blood 
coagulation cascade, such as factors VIIa and Xa, are also 
structurally related to thrombin. Thus, thrombin inhibitors 
for potential drug development need to discriminate 
against these proteases. 
In this work, we present the design and synthesis of novel, 
nonpeptidic, selective thrombin inhibitors and we confirm 
their binding mode by X-ray crystallography on two 
thrombin-inhibitor complexes. An elegant optical resolu- 
tion of the new inhibitors is described. Binding affinity 
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Figure 1 
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Schematic representation of the complex formed by thrombin and 
ent-1, according to the X-ray crystal structure [Q]. 
data correlated with X-ray structural information provide a 
detailed insight into the nature and strength of weak inter- 
molecular bonding interactions at the thrombin active site. 
Results and discussion 
Inhibitor design 
To increase the selectivity of new inhibitors for thrombin 
over trypsin, the X-ray crystal structure of the complex 
formed between thrombin and the lead molecule 1 
(Fig. 1) [9] was carefully examined. Only one enantiomer 
of the racemic mixture of compound 1 was found in the 
active site of thrombin, as expected from molecular mod- 
eling experiments [lo]. This enantiomer was named ent-1 
(ent= enantiomeric). 
The amidinium sidechain of ent-1 binds well in the recog- 
nition pocket Sl of the enzyme. It interacts with the car- 
boxylate group of Asp189 at the bottom of the pocket and 
forms additional hydrogen bonds to the carbonyl group of 
Gly219 and to a water molecule (not shown in Fig. 1). 
The aromatic part of the piperonyl (benzo[l,3]dioxol- 
S-ylmethyl) group of ent-1 is located in the large 
hydrophobic D-pocket of thrombin (called D because it is 
‘distal’ from the catalytic Ser195 [S]) and is involved in a 
CH..rt interaction with Trp215. One oxygen atom of the 
piperonyl group forms a hydrogen bond with Tyr60A. 
Another hydrogen bond exists between the NH of 
Gly216 and an imide C=O group of ent-1. The other, 
‘upper’ C=O group of the inhibitor points into the small, 
hydrophobic P-pocket (‘proximal’) of thrombin. The 
transfer of this C-O group from aqueous solution to the 
hydrophobic pocket requires desolvation energy and is 
therefore unfavorable. The P-pocket is formed by an 
insertion loop in the structure of the enzyme and is 
lacking in other, related serine proteases such as trypsin. 
This P-pocket is unique to thrombin and its occupancy 
by a stereoelectronically complementary group provides a 
significant contribution to the narrow substrate specificity 
of the enzyme. Therefore, by removing the ‘upper’ C=O 
group in ent-1, which lacks this complementarity, or by 
replacing it with hydrophobic residues, we expected 
binding selectivity to be increased. 
Synthesis 
The key step in the synthesis of the starting materials rat-2 
and rat-3 involved the formation of the central bicyclic 
skeleton by an azomethine ylide 1,3-dipolar cycloaddition 
[ 111. The synthesis was carried out as previously described 
[9]. The conversion of one C=O into one CH, group in 
rat-2 was achieved by treatment with Li[Et,BH] in 
tetrahydrofuran (THF) followed by Na[BH,CN] in trifluo- 
roacetic acid (TFA) (Fig. 2). This reaction sequence 
yielded both regioisomeric lactams rat-4 and rat-5, which 
were separated and converted into the corresponding 
nitriles rat-6 and rat-7, respectively, using CuCN in reflux- 
ing dimethylformamide (DMF). The synthesis of the ami- 
dinium salts rat-8 and rat-9 was completed by a Pinner 
reaction [ 121. 
For the replacement of the upper C=O group by a 
hydrophobic residue, rat-2 was reduced with Li[Et,BH] to 
yield a mixture of two regioisomeric hydroxylactams 
(Fig. 2). After separation, reaction with toluene-4-sullinic 
acid afforded the exe-sulfone rat-10 [13]. Nucleophilic dis- 
placement by organometallic reagents prepared from the 
corresponding Grignard reagents and zinc chloride afforded 
the exe-alkyl-substituted or cycloalkyl-substituted lactams 
rat-lla,b,d,e [13], which were converted via the nitriles 
rat-lZa,b,d,e into the amidinium salts rat-13a,b,d,e. 
Attempts to find a more direct way of replacing one C=O 
group of rat-2 by reaction with MeMgCl followed by 
reduction with Na[BH,CN] gave the endo-methylated 
lactam rat-14 as the only product, which was also converted 
via nitrile rat-15 into the amidinium salt rat-16. 
The same sequence of synthetic steps was used for the 
transformation of imide rat-3, with a tricyclic core struc- 
ture, into the exe-sulfone rat-17 and, via rat-Mb-f and 
rat-19b-f, into the amidinium salts rat-ZOb-f (Fig. 3). 
Biological results 
With their rigid central bicyclic or tricyclic cores, all 
inhibitors discussed in this study have highly constrained 
conformations and it is therefore reasonable to assume 
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Figure 2 
Synthesis of the racemic inhibitors 8, 9, 
13a,b,d,e and 16. (i) Li[Et,BHl, 
tetrahydrofuran (THF), -78+0%, 1 h. 
(ii) Na[BH,CN], trifluoroacetic acid (TFA), 
room temperature (r.t.), 5 h, 49% (rat-4) and 
31% (rat-5). (iii) C&N, DMF, reflux, 17-30 h, 
62% (w-6), 65% (w-7) 62O/o (rat-12a), 
40% (rat-1 2b), 55% (rat-1 2d). 62% 
(rat-1 2e), 65% (rat-1 5). (iv) CH,OH, HCI 
(gas), CHCI,, 4”C, 24 h. (v) NH,, CHsOH, 
65”C, 3.5 h, 84% (rat-8) 82% (rat-9) 90% 
(rat-13a), 90% (rat-1 3b), 66% (rat-1 3d), 
74% (rat-1 3e), 83% (rat-16). (vi) Li[Et,BH], 
THF, -78+O”C, 2 h, 67%. (vii) Toluene-4- 
sulfinic acid, CaCI,, CH,CI,, r.t., 19 h, 74%. 
(viii) Z&I,, RMgCl or RMgBr, CH,CI,, 
O’C+r.t., 13-36 h, 750/o (rat-1 1 a), 76% 
(rat-1 1 b), 35% (rat-1 1 d), 31 O/o (rat-1 1 e). 
(ix) MeMgCI, THF, r.t., 13 h. (x) Na[BH,CNl, 
MeOH, TFA, r.t., 2 h, 94%. 
rat-4 X=Br 
rat-6 X=CN rat-7 X=CN 
8r X 
(ix),(x) 
\ 
rat-1 la,b,d,e X = Br 
(iii) 
rat-12a,b,d,e X = CN 
oAo (iv), (VI 
X rat-13a,b,d,e X = C(NH2)s+CI- 
R’ 
a Methyl 
b Ethyl 
d Isopropyl 
e Cyclohexyl 
c 
rat-14 
(iii) 
c 
fat-15 
(iv),(v) 
rat- 16 
X=Br 
X=CN 
X = C(NH2) s+Cl- 
that they each bind to thrombin with an identical binding exe-methyl group at C(4), which should bind into the 
mode. Using this hypothesis, which is further validated by P-pocket, both the affinity (AAG,,,,= -0.7 kcal mol-l) 
the X-ray crystallographic findings described below, we and the selectivity increased compared to lactam rat-8. 
could evaluate the contributions made by single sub- Nevertheless, the methylated lactam rat-13a remained 
stituents on the central inhibitor core to the measured free less potent than imide rat-21. A large improvement in 
energy of binding. Table 1 shows the binding affinities both the affinity and the selectivity, compared to rat-8, 
[14,15] of the bicyclic inhibitors with various residues at resulted from the introduction of an ethyl group (rat-13b, 
C(4). A comparison of the affinities of imide rat-21, which AAG s+t3,, =-2.5 kcal mol-l), and an isopropyl group 
was prepared as for rat-1 [9], and lactam rat-8 towards improved parameters still further (rat-13d, AAGs+13d = 
thrombin indicated, quite surprisingly, that the imide -3.2 kcal mol-l). With a Ki value of 30 nM and a 223-fold 
bound by 1.5 kcalmol-’ better than the lactam. Appar- higher affinity for thrombin over trypsin, rat-13d was the 
ently, it is more favorable to have a C=O group of poor most potent and most selective among the inhibitors with 
electronic complementarity filling the hydrophobic a bicyclic core. A cyclohexyl substituent is too large for 
P-pocket of the enzyme and pointing onto the surfaces of optimal binding in the P-pocket and both the affinity and 
the aromatic rings of Tyr60A and Trp6OD than to leave the selectivity of rat-13e were clearly reduced, compared 
this pocket empty. When the inhibitor (rat-13a) had an to rat-13d. 
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Figure 3 
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Synthesis of the inhibitors rat-20b-f. (i) Li[Et,BHl, THF, -78+O”C, 
30 min. (ii) Toluene-4sulfinic acid, CaCI,, CH,CI,, room temperature 
(r.t.), 24 h, 73%. (iii) ZnCI,, RMgCl or RMgBr, CH,CI,, 0%-+r.t., 
13-36 h, 48% (rat-18c), 52% (rat-18d), 21 o/, (rat-18e), 90% 
(rat-18f). (iv) CuCN, dimethylformamide (DMF), reflux, 17-30 h, 31% 
(rat-19b, yield from rat-1 7), 71% (rat-1 SC), 560/o (rat-1 9d), 86% 
(rat-1 se), 61 o/o (rat-1 90. (v) CHsOH, HCI (g), CHCI,, 4’C, 24 h. 
(vi) NH,, CHsOH, 65°C 3.5 h, 78% (rat-20b), 82% (rat-~OC), 79O/o 
(rat-20d), 72% (rat-20e), 89% (rat-20f). 
Inhibitors lacking the ‘lower’ C=O group at C(6) were, as 
expected, less active than the imide rat-21 (Table Z), 
because they were unable to form a hydrogen bond to the 
backbone NH of Gly216 (see Fig. 1). This hydrogen bond 
is not essential for an inhibitor to be active, because the 
binding affinities of imide rat-21 and lactam rat-9 differ 
by only AAG21,9= +0.8 kcalmol-i. This value is in good 
agreement with data from Fersht et a/. [16] who observed 
losses in the free energy of binding of OS-l.5 kcalmoI1 
by deleting uncharged hydrogen bonds in enzyme-sub- 
strate complexes using site-directed mutagenesis. Lactam 
rat-16, with an en&methyl group at C(6), still showed 
Table 1 
some affinity towards thrombin and trypsin; we cannot 
rule out the possibility that this inhibitor has a different 
binding mode, however. 
The inhibitors with a tricyclic core structure (Table 3) are 
much more active and selective overall than those with a 
bicyclic one (Table 2). The three lactams with an exe-ethyl 
(rat-ZOb), an exe-cyclopropyl group (rat-2%) and an exo- 
isopropyl group (rat-20d) at C(1) showed high and similar 
binding affinities for thrombin. As in the bicyclic series, 
the inhibitor with the exe-isopropyl substituent (nzc-20d) 
was the most selective. This compound (Ki= 13nM) was 
Binding affinities of thrombin inhibitors with bicyclic core structures modified at C(4) and their selectivity with respect to trypsin. 
~ Compound 
rat-21 
rat-8 
rat-13a 
rat-1 3b 
HCI rat-1 3d 
Ki (PM) AAG+ 
R3 R4 Thrombin Trypsin Selectivity* 0 
0’ 0.5 1.1 2.2 -1.5 
H H 6.2 31 5 0 
Methyl H 2.0 64 32 -0.7 
Ethyl H 0.095 7.3 77 -2.5 
Isopropyl H 0.030 6.7 223 -3.2 
fat-1 3e Cyclohexyl H 0.86 33 38 -1.2 
*Ki (trypsin) / Ki (thrombin). Contributions of substituents at C(4) to the binding free energy at 298 K. AAG = AG(rac-8)-AG(x); x: racemic 
compounds 21 and 13a,b,d,e. AG = - RT In K,. 
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Table 2 
Binding affinities of thrombin inhibitors with bicyclic core structure modified at C(6) and their selectivity with respect to trypsin. 
HCI 
-NH? 
Compound Rs R4 
K, (Q.4 AAG’ 
Thrombin Trvpsin Selectivity* (kcal mol-I) 
rat-21 0 0.5 1 .l 2.2 0 
rat-9 H H 2.0 64 32 +0.8 
rat-1 6 H Methyl 9.2 40 4.3 +1.7 
*K, (trypsin) IK, (thrombin). ‘Destabilization AAG of the thrombin-inhibitor complex by removal or replacement of one carbonyl group of rat-21. 
AAG=AG(rac-21) -AG(x); x: racemic compounds 9 and 16. 
not only selective for thrombin over trypsin 
[Ki(trypsin)= 9.9 FM], but also showed high selectivity 
when tested for binding to the coagulation factors Xa 
(Ki = 140 FM) and VIIa (Ki >500 pM). 
Inhibitor rat-20d is a mimetic of the natural thrombin 
substrate fibrinogen. This protein binds in the D-pocket 
with the phenyl group of a phenylalanine (rat-ZOd uses a 
piperonyl group), in the P-pocket with the isopropyl 
group of a valine (rat-20d also uses an isopropyl group), 
and in the Sl-pocket with the guanidinium sidechain of 
an arginine residue (rat-2Od uses an amidinium group) 
[17]. A substantial loss in affinity was again detected for 
inhibitors with larger substituents at C(4) - such as exo- 
cyclohexyl (rat-2Oe) and exe-phenyl (rat-2Of). These 
groups are too voluminous to be incorporated into the 
P-pocket of thrombin. 
The observation that small hydrophobic moieties are pref- 
erentially bound in the P-pocket of thrombin confirms the 
Table 3 
results from the literature [15]. Obviously, the loop in 
thrombin that forms the P-pocket is rather rigid and can 
only adapt to larger groups in the inhibitor to a limited 
extent. A methyl group, however, is too small to fill the 
space available in this pocket. 
Optical resolution of racdOd 
All biological activities discussed above refer to racemic 
mixtures of the inhibitors. Based on the molecular model- 
ing experiments, we expected a very large difference in 
the affinity of the two enantiomers towards thrombin. 
Consequently, we carried out the optical resolution (Fig. 4) 
of the most selective inhibitor rat-20d. Imide rat-3 was 
reduced to the hydroxylactam and subsequently treated 
with methyl D-(-)-mandelate and a catalytic amount of 
pyridinium-4-toluenesulfonate in refluxing toluene. The 
resulting diastereoisomeric ethers 23 and 24 were sepa- 
rated by column chromatography over silica gel and con- 
verted into the enantiomerically pure sulfones (+)-17 
(enantiomeric purity 96.5%) and (-)-17 (enantiomeric 
Binding affinities of thrombin inhibitors with tricyclic core structure modified at C(1) and their selectivity with respect to trypsin. 
h- 
HN 
HCI 
NHz 
Compound R’ R2 
K, (I-M AAG+ 
Thrombin Trypsin Selectivity* (kcal mol-l) 
rat-1 * 0 0.09 0.70 7.8 0 
rat-20b Ethyl H 0.0081 1.7 210 -1.4 
rat-2Oc Cyclopropyl H 0.010 2.3 230 -1.3 
rat-20d Isopropyl H 0.013 9.9 760 -1 .l 
rat-20e Cyclohexyl H 1.7 4.4 2.6 +1.7 
rat-20f Phenyl H 1.4 5.2 3.6 +1.6 
*K, (trypsin)/K, (thrombin). Stabilization or destabilization AAG of the thrombin-inhibitor complex by replacement of one carbonyl group of 1 
AAG=AG(rac-1) -AG(x); x: racemic compounds 20b-f. Vrom 191. 
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Figure 4 
Optical resolution of sulfone fat-1 7. 
(i) Li[Et,BHl, THF, -78+O”C, 30min. 
(ii) Methyl o-(-)-mandelate, pyridinium-4- 
toluenesulfonate, toluene, reflux, 6 h, 61% 
(23), 64% (24). (iii) Toluene-4-sulfinic acid, 
CaCI,, CH,CI,, r.t., 12 h. (+)-17: 73%. 
C-J-1 7: 91 o/,. 
\ \ 
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purity ~99.5%). A further purification of (+)-17 was 
achieved by recrystallization from ethyl acetate / hexane. 
The very insoluble racemate crystallized out, leaving the 
remaining soluble (+)-17 with an enantiomeric purity of 
higher than 99: 1,. 
The enantiomeric sulfones (+)-17 and (-)-17 were then 
converted into the corresponding amidinium salts (+)-20d 
and (-)-2Od by the procedure used for the preparation of 
the racemic mixture. Enantiomer (+)-20d bound to throm- 
bin with Ki=7nM and a selectivity KJtrypsin)/KJthrom- 
bin) of 740. It was therefore 800 times more active than 
(-)-20d (Ki=5.6~M, selectivity 21). The more potent 
enantiomer was the one found in the crystal structure of 
the complex formed between thrombin and (+)-20d (see 
below), and, consequently, we assigned the (lR,3aS,4R, 
8aS,8bR)-configuration to (+)-20d (numbering according 
to Fig. 3). 
Confirmation of the binding modes by X-ray crystallography 
The X-ray crystal structures of the complexes of lactams 
ent-9 (resolution 2.1A) and (+)-20d (resolution 1.93A) 
with thrombin (Figs $6) showed that the more potent 
inhibitor enantiomers were incorporated into the complex 
and adopted the same binding mode in the enzyme active 
site as did the imide ent-1 [9]. This was as expected from 
molecular modeling studies. The observation of a nearly 
identical binding mode in three crystal structures, as a 
result of the high degree of structural preorganization of 
the inhibitors, fully validates the correlations between 
Figure 5 
The active site region in the X-ray crystal structure of the complex 
between thrombin and ent-9. Hydrogen bonds are represented as 
dashed lines. 
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Figure 6 
The active site region in the X-ray crystal structure of the complex 
between thrombin and (+)-20d. Hydrogen bonds are represented as 
dashed lines. 
changes in binding free energy and the bonding differ- 
ences between individual substituents that were drawn in 
the molecular recognition analysis above. 
Interestingly, removal of the C=O group at C(6) upon 
passing from imide ent-1 (Fig. 1) to lactam ent-9 (Fig. 5) 
did not induce a significant positional shift of the bicyclic 
core structure within the protein, although the hydrogen 
bond to Gly216 was lacking. Apparently, the backbone 
NH of Gly216 does not require strong solvation through 
hydrogen bonding to the inhibitor, as was also evident 
from the modest difference in the free energy of binding 
between the complexes of imide rat-21 and lactam ~6-9 
(Table 2). The low energetic costs for the loss of this 
intermolecular hydrogen bond can be explained by the 
electrostatic stabilization of the partially positively- 
charged hydrogen atom in the NH group by the 7c-elec- 
trons of the phenylamidinium residue of ent-9 which is 
oriented cofacially to the planar -CO-C-NH- moiety of 
Gly216 at a distance of -3.6A. In the planar glycine 
residue, dipolar compensation between the antiparallel 
Figure 7 
The active site region in the X-ray crystal structure of the complex 
between thrombin and (+)-20d. Space filling representation of (+)-20d 
and solvent-accessible surface of thrombin. 
C=O and N-H dipoles should provide substantial internal 
solvation. The advantages of the hydrogen bond between 
the lower carbonyl oxygen atom at C(6) of ent-1 and 
(+)-20d and the NH of Gly216 are partially compensated 
for by repulsive secondary electrostatic interactions [18] 
between this oxygen atom and the carbonyl oxygen atom 
of Gly216, located in close contact at 2.9A. Also, favorable 
dispersion interactions between the H&2(6) group in 
ent-9 and the CH-CH, moiety of Trp215, as well as the 
corresponding hydrophobic desolvation, should partially 
compensate for the loss of the hydrogen bond to Gly216. 
The isopropyl substituent of (+)-20d fits well into the 
P-pocket as shown in Figures 6 and 7. Its pro-S methyl 
group (on the left side) has close C..C contacts (3.3-4.1 A) 
with an aromatic carbon atom of TyrbOA, the CH, group 
of His57, and a CH, group of Leu99. Furthermore, the 
pro-S-CH3-CH moiety packs intramolecularly against the 
piperonyl group. Hydrophobic packing of inhibitor sub- 
stituents that bind into the P-pocket and D-pocket of the 
enzyme is often seen in thrombin-inhibitor complexes [S]. 
The pro-R methyl group has short C..C contacts with aro- 
matic carbon atoms of Tyr60A and TrpbOD, that form the 
‘ceiling’ and the right wall of the P-pocket, as well as with 
a heterocyclic carbon atom of His57. 
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Significance 
Thrombin is a trypsin-like serine protease that is central 
in the processes of hemostasis and thrombosis. The ther- 
apeutic control of thrombin activity by direct acting, 
selective inhibitors could have advantages over the cur- 
rently used antithrombotics heparin and coumarins. In 
this work, we present the structure-based design and 
synthesis of a series of potent and selective novel throm- 
bin inhibitors. These compounds have a rigid bicyclic or 
tricyclic core structure and are highly preorganized for 
binding to thrombin. The nonpeptidic nature of this class 
of inhibitors makes them interesting lead molecules for 
the continuing search for compounds with optimal phar- 
macological properties. Future analogs have the poten- 
tial to be useful for the treatment and prevention of 
thrombotic diseases. The identical binding mode of the 
inhibitors at the thrombin active site, which is a direct 
consequence of their high degree of conformational pre- 
organization by the bicyclic and tricyclic core structures, 
provided the basis for sound biological molecular recog- 
nition studies. Thus, measured changes in the free 
energy of binding could be directly correlated with the 
bonding contributions of individual substituents of the 
inhibitors and valuable information on the magnitude of 
individual intermolecular interactions was obtained. 
This study demonstrates that defined mutations in 
highly preorganized inhibitors provide an attractive 
alternative to site-directed mutagenesis in exploring mol- 
ecular recognition phenomena at enzyme active sites. 
Materials and methods 
Molecular modeling 
The design of the target molecules was carried out on a Silicon 
Graphics Crimson workstation using the molecular modeling 
program MOLOC (F. Hoffmann-La Roche) [lo]. Modeling procedure: 
the proposed inhibitor was minimized separately and docked manu- 
ally into its expected binding site. The coordinates of thrombin were 
fixed and the inhibitor was minimized inside the enzyme. 
Analytical characterization of racdOd 
Melting point (m.p.) 210-215%. ‘H-NMR (200 MHz, (CD,),SO, see 
Fig. 3 for the numbering of atoms): 6 0.65 (d, I = 6.4, 3H, CH,); 
0.89 (d, J= 6.7, 3 H, CH,); 1.63 (m, 2 H, H-C(7) and H-C(8)); 1.90 
(m, 2H, H-C(7) and H-C(8)); 2.09 (m, 1 H, CH-C(1)); 2.37-2.62 
(m, 2 H, H-C(8b) and H-C(6)); 2.82 (m, 1 H, H-C(6)); 3.17 (m, 2 H, 
H-C(l) and H-C(8a)); 3.36 (m, 1 H, H-C(3a)); 3.77, 4.53 (AB, J = 
14.9, 2 H, CH,-N(2)); 4.18 (d, J = 7.5, 1 H, H-C(4)); 6.02 (m, 2 H, 
OCH,O); 6.70, 6.89 (AB, J= 7.9, 2 H, piperonyl aromatic); 6.74 (s, 
1 H, piperonyl aromatic); 7.56, 7.76 (AB, J=8.3, 4H, 4-amidini- 
umphenyl); 9.13 (s, 2 H, C(NHH),); 9.34 (s, 2 H, C(NHH),). Desorp 
tion electron impact high resolution mass spectrum: calc’d for 
C,,H,,N,O, ([M- HCI]+ 460.2474; found 480.2488. 
Analytical characterization of optically pure compounds 
The enantiomeric purity of the sulfones (+)-17 and (-)-17 was deter- 
mined by analytical HPLC (AcOEt : hexane 1 :l) on a commercial (S,S)- 
Whelk-01 column (250 mm x 4.6 mm I.D.) from Regis, 8210 Austin 
Ave, Morton Grove, IL 60053, USA [191; detection at 254 nm; separa- 
tion factor ol=1.8. (+)-17: [or]:+243 (c 1.00, CHCI,), enantiomeric 
purity >99:1.(-)-17: [a]2,5-237 (c 1 .OO, CHCI,), enantiomeric purity 
>99.5:0.5. (+)-20d: decomposition > 15O”C, [a]:+1 42 (c 1 .OO, 
CHCI,); (-)-20d: decomposition > 150°C [al:-1 45 (c 0.99, CHCI,). 
Full experimental protocols for the syntheses of the inhibitors described 
in this work will be provided in a full paper. All new compounds 
reported here were fully characterized by mass spectrometry, tsC-NMR, 
‘H-NMR, IR, and elemental analysis or high resolution mass spectra. 
X-ray crystal structure determination 
Crystals of C2 symmetry of human c-Y-thrombin were grown in the pres- 
ence of a carboxy-terminal hirudin peptide Ides-amino Asp55 hirudin 
55-651 as inhibitor in the anion-binding exosite, but with no active-site 
inhibitor. Compounds rat-9 and rat-20d were diffused into crystals 
overnight at a concentration of 1 mM. Diffraction data were measured 
using a 30cm image plate (Marresearch) on an FR591 X-ray generator 
(Delft Instruments) equipped with double focusing mirrors (Supper) run 
at 3.5 kW. Exposure times were 300 s for 0.5” frames and complete 
data were obtained in a 120” scan. Only the higher-affinity enantiomer 
of the two inhibitors was found in the X-ray crystal structure. For the 
complex of ent-9, the detector distance was 160 mm, the limiting reso- 
lution 2.1 p, and the unit cell dimensions a=71.99& b=72.52A, 
c= 73.20A, and 8= 100.80”. The merging R-factor on intensities was 
3.4O/o and IICI=3.1 in the outermost data shell. Refinement with X-plor 
gave final crystallographic R-factors of 14.9% (working) and 19.8% 
(free), with rms (root mean square) bond errors of 0.01 A and rms angle 
errors of 1.86’. For the complex of (+)-20d the detector distance was 
140mm, the limiting resolution 1.93A, and the unit cell dimensions 
were a=71.95A, b=72.41 A, c=73.41 A, and 8=101.037”. Refine- 
ment with X-plor gave aOfinal crystallographic R-factor of 15.9%, with 
rms bond errors of 0.01 A and rms angle errors of 1.84”. 
Determination of inhibition constants 
The affinity of the thrombin inhibitors was determined according to 
[14,15] (chromogenic substrate S-2238). An exhaustive protocol of 
the binding assay identical to the one used in this study is provided 
in [15]. 
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